Copenhagen-based biotech firm, Hemab Therapeutics, has raised $157 million in a Series C funding round led by Sofinnova Partners to advance its lead programs and expand its pipeline of therapies for rare bleeding disorders.
- Established in 2020 by Benny Sørensen, Hemab Therapeutics is a clinical-stage biotechnology company developing prophylactic antibody-based treatments for rare bleeding and thrombotic disorders that lack effective therapies.
- Based in Cambridge, Massachusetts, and Copenhagen, Denmark, the company focuses on monoclonal and bispecific antibodies designed to restore clotting function in patients with genetic deficiencies that cause excessive bleeding.
- Hemab’s lead program, sutacimig (formerly HMB-001), stabilizes and directs Factor VIIa to activated platelets to promote clot formation in Glanzmann thrombasthenia and other disorders, while its second candidate, HMB-002, targets the C-terminal region of Von Willebrand Factor to prevent its degradation and increase circulating levels in patients with Von Willebrand disease.
- The company’s broader pipeline applies similar antibody engineering approaches to develop preventive, rather than reactive, therapies for a range of inherited blood-clotting disorders.
Details of the deal
- The Series C was led by Sofinnova Partners with backing from Avoro Capital Advisors, RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Maj Invest Equity, and Rock Springs Capital.
- Hemab Therapeutics will use the $157 million raised to advance late-stage studies of sutacimig for Glanzmann thrombasthenia and Factor VII deficiency, progress HMB-002 for Von Willebrand disease toward registration, and bring new candidates such as HMB-003 into clinical development while strengthening its research and development capabilities.
"Hemab’s unprecedented deep domain expertise in clotting science, combined with our proven capabilities in advancing programs from early development through approval and commercialisation, uniquely positions us to deliver breakthrough therapies. This funding accelerates our mission of transforming lives for people who have waited far too long," explains Benny Sorensen, CEO of Hemab.
